Teleflex Celebrates 400,000 Sufferers Handled With the Minimally Invasive UroLift® System

WAYNE, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a number one world supplier of medical applied sciences, at the moment introduced that 400,000 sufferers have now been handled with the UroLift^® System,¹ a secure, efficient and minimally invasive remedy choice for benign prostatic hyperplasia (BPH), or enlarged prostate.² The UroLift^® System is the primary minimally invasive BPH process chosen by urologists and their sufferers within the U.S.³ The 5-year L.I.F.T. research outcomes exhibit UroLift^® System sturdiness with a surgical retreatment fee of about 2-3% per 12 months and 13.6% whole over 5 years.²

BPH is a non-cancerous enlargement of the prostate, occurring naturally as males age, which might trigger urinary issues, lower high quality of life, and interrupt sleep.⁴ Greater than 14 million males within the U.S. search remedy for the situation yearly.³

“The UroLift^® System is a confirmed remedy methodology in my observe for sufferers looking for reduction from an enlarged prostate,” stated Steven Gange, M.D., F.A.C.S., of Summit Urology Group and Affiliate Medical Director of the Teleflex Interventional Urology Enterprise Unit. “For males with BPH who need to get off medicines, the UroLift^® System could be a superb minimally invasive choice that gives speedy reduction and low threat of everlasting unwanted side effects.”

Teleflex just lately carried out a survey of 1,000 U.S. males aged 45+ who’re experiencing BPH signs to raised perceive the remedy journey and affected person conduct surrounding BPH.⁵

Key findings embody:

• 70% of males surveyed, who have been as younger as 45, indicated medicines have been advisable as not less than one choice for treating BPH.⁶

• Practically half of the respondents on remedy (44%) are desirous about various remedy choices.⁷

“Urologists can change applicable BPH sufferers’ journeys for the higher, with confidence, by providing them the UroLift^® System,” stated Kevin Hardage, President and Normal Supervisor of Teleflex Interventional Urology. “At Teleflex, we’re honored to play an necessary function in enhancing the standard of lifetime of lots of of 1000’s of males with BPH.”

In regards to the UroLift^® System
The UroLift^® System is a minimally invasive remedy for decrease urinary tract signs on account of benign prostatic hyperplasia (BPH). It’s indicated for the remedy of signs of an enlarged prostate as much as 100 cc in males 45 years or older (50 years exterior U.S.). The UroLift^® everlasting implants, which could be delivered throughout an outpatient process, relieve prostate obstruction with out heating, reducing, destruction of, or eradicating prostate tissue. The UroLift^® System can be utilized to deal with a broad spectrum of anatomies, together with obstructive median lobe.⁸ It’s the solely main BPH process proven to not trigger new onset, sustained erectile or ejaculatory dysfunction^.*2,9-10 The L.I.F.T. research has confirmed UroLift^® System sturdiness out to five years with a surgical retreatment fee of 13.6% over 5 years or about 2-3% per 12 months.² Commonest opposed occasions are short-term and may embody hematuria, dysuria, micturition urgency, pelvic ache, and urge incontinence.¹¹ Uncommon unwanted side effects, together with bleeding and an infection, could result in a critical consequence and will require intervention. Particular person outcomes could differ. The prostatic urethral carry process (utilizing the UroLift^® System) is advisable for the remedy of BPH in each the 2021 American Urological Affiliation and 2022 European Affiliation of Urology scientific tips. Greater than 400,000 males have been handled with the UroLift^® System in choose markets worldwide.¹
Study extra at UroLift.com. Rx solely.

About Teleflex Included
Teleflex is a worldwide supplier of medical applied sciences designed to enhance the well being and high quality of individuals’s lives. We apply function pushed innovation – a relentless pursuit of figuring out unmet scientific wants – to profit sufferers and healthcare suppliers. Our portfolio is numerous, with options within the fields of vascular entry, interventional cardiology and radiology, anesthesia, emergency drugs, surgical, urology and respiratory care. Teleflex workers worldwide are united within the understanding that what we do daily makes a distinction. For extra data, please go to teleflex.com.

Ahead-Trying Statements
Any statements contained on this press launch that don’t describe historic details could represent forward-looking statements. Any forward-looking statements contained herein are based mostly on our administration’s present beliefs and expectations, however are topic to plenty of dangers, uncertainties and adjustments in circumstances, which can trigger precise outcomes or firm actions to vary materially from what’s expressed or implied by these statements. These dangers and uncertainties are recognized and described in additional element in our filings with the Securities and Trade Fee, together with our Annual Report on Kind 10-Ok.

Contacts:

Teleflex Included:
Lawrence Keusch
Vice President, Investor Relations and Technique Growth
John Hsu, CFA
Vice President, Investor Relations
Investors.teleflex.com
610-948-2836

Media:
Nicole Osmer
[email protected]
650-454-0504

*No situations of recent, sustained erectile or ejaculatory dysfunction within the L.I.F.T. pivotal research.

References:

1. Administration estimate based mostly on product gross sales as of December 2022. Information on file Teleflex Interventional Urology.

2. Roehrborn, Can J Urol 2017.

3. U.S. 2022 estimates based mostly on US Market Mannequin 2022-24 (5-17-22 FINAL), which is partially based mostly on Symphony Well being PatientSource^® 2018-21, as is and with no representations/warranties, together with accuracy or completeness.

4. Speakman, BJUI 2014.

5. Survey of US males aged 45+ who’ve skilled signs generally related to BPH (enlarged prostate), carried out by Teleflex in 2022. Information on file, n=1000.

6. Survey of US males aged 45+, who’ve been recognized with BPH (enlarged prostate), are affected by not less than one urinary symptom, and who spoke to their physician about their BPH remedy, carried out by Teleflex in 2022. Information on file, n=1,001

7. Survey of US males aged 45+, who’ve been recognized with BPH (enlarged prostate), are affected by not less than one urinary symptom, who didn’t get a remedy advice from their physician about their BPH remedy, or did get a advice from their physician about their BPH remedy and selected medicines, carried out by Teleflex in 2022. Information on file, n=714

8. Rukstalis, Prostate Most cancers and Prostatic Dis 2018.

9. AUA BPH Tips 2003, 2021.

10. McVary, J Intercourse Med 2016.

11. Roehrborn, J Urology 2013.

Teleflex is the house of Arrow^®, Deknatel^®, LMA^®, Pilling^®, QuikClot^®, Rüsch^®, UroLift^®, and Weck^® – trusted manufacturers united by a typical sense of function.

Teleflex, the Teleflex brand, Arrow, Deknatel, LMA, Pilling, QuickClot, Rusch, UroLift and Weck are emblems or registered emblems of Teleflex Included or its associates, within the U.S. and/or different nations.

© 2022 Teleflex Included. All rights reserved. MAC02612-01 Rev A